Targeting Hypoxia & Beyond Cancer
More than 40% of solid tumors are thought to harbour hypoxic (oxygen deprived) regions/cells. Unfortunately, hypoxia is not detected by the most commonly-used PET radiopharmaceutical scans; this is a critical shortcoming, given that [18F]FDG is considered by many to be the ‘gold standard’ for tumor detection using PET. Unlike [18F]FDG, WWiKY’s Hypoxycin pharmaceuticals are not designed to be general tumor-detecting agents; they are designed to detect hypoxic regions in tumors and are therefore a more accurate and effective form of scanning technology.
Focal tumor hypoxia imaging and hypoxia-targeted radiotherapy is particularly important for Stage II/III lung, head, neck and cervix cancers, and glioblastomas. Beyond that, this imaging and radiotherapy is used in other diseases that demonstrate hypoxia, such as chronic head injury/concussion, Alzheimer’s disease, diabetes, stroke, anaerobic infections and rheumatic disorders.
The relevance of WWiKY pharmaceuticals reflects the oncology community’s acknowledgement of the critical role of hypoxia in tumor management.
A True Theranostic Approach
WWiKY Hypoxycin pharmaceuticals are designed for use in molecular imaging/diagnoses AND radiotherapy in hospitals, private clinics or research institutions, creating a true One-Drug Theranostic Approach (therapy + diagnostic). The versatility of WWiKY Theranosticspotentially creates a global yet untapped market opportunity for managing many types of cancer and other diseases in the future